Torray Investment Partners LLC Increases Stock Position in AbbVie Inc. $ABBV

Torray Investment Partners LLC lifted its holdings in AbbVie Inc. (NYSE:ABBV) by 267.7% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 95,042 shares of the company’s stock after purchasing an additional 69,195 shares during the period. AbbVie comprises 2.6% of Torray Investment Partners LLC’s holdings, making the stock its 13th biggest position. Torray Investment Partners LLC’s holdings in AbbVie were worth $17,642,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. TD Capital Management LLC lifted its position in shares of AbbVie by 82.9% in the 1st quarter. TD Capital Management LLC now owns 128 shares of the company’s stock worth $27,000 after purchasing an additional 58 shares during the period. Marshall & Sullivan Inc. WA purchased a new stake in shares of AbbVie in the 2nd quarter worth approximately $25,000. Abound Financial LLC purchased a new stake in shares of AbbVie in the 1st quarter worth approximately $30,000. Cypress Capital Management LLC WY purchased a new stake in shares of AbbVie in the 1st quarter worth approximately $35,000. Finally, Bear Mountain Capital Inc. lifted its position in shares of AbbVie by 480.6% in the 2nd quarter. Bear Mountain Capital Inc. now owns 209 shares of the company’s stock worth $40,000 after purchasing an additional 173 shares during the period. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Trading Down 4.4%

Shares of AbbVie stock opened at $218.14 on Monday. The company has a current ratio of 0.74, a quick ratio of 0.61 and a debt-to-equity ratio of 44.14. AbbVie Inc. has a 12-month low of $163.81 and a 12-month high of $244.81. The firm has a market capitalization of $385.35 billion, a price-to-earnings ratio of 103.87, a PEG ratio of 1.42 and a beta of 0.51. The firm’s 50 day simple moving average is $222.42 and its two-hundred day simple moving average is $201.15.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a net margin of 6.45% and a return on equity of 699.66%. The business had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.58 billion. During the same quarter in the prior year, the business posted $3.00 EPS. AbbVie’s revenue for the quarter was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Analysts predict that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 3.2%. This is a boost from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date of this dividend is Friday, January 16th. AbbVie’s dividend payout ratio is 524.24%.

Insider Buying and Selling at AbbVie

In related news, EVP Azita Saleki-Gerhardt sold 42,370 shares of the firm’s stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $198.42, for a total transaction of $8,407,055.40. Following the completion of the transaction, the executive vice president owned 177,292 shares of the company’s stock, valued at $35,178,278.64. This trade represents a 19.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Nicholas Donoghoe sold 13,295 shares of the firm’s stock in a transaction on Tuesday, August 5th. The stock was sold at an average price of $198.51, for a total transaction of $2,639,190.45. Following the transaction, the executive vice president directly owned 58,247 shares of the company’s stock, valued at approximately $11,562,611.97. This trade represents a 18.58% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.25% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently commented on ABBV shares. HSBC set a $225.00 price objective on shares of AbbVie in a research note on Thursday, October 2nd. JPMorgan Chase & Co. boosted their price objective on shares of AbbVie from $200.00 to $235.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 16th. Wall Street Zen upgraded shares of AbbVie from a “hold” rating to a “buy” rating in a research note on Saturday, October 25th. Hsbc Global Res lowered shares of AbbVie from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 1st. Finally, Piper Sandler boosted their price objective on shares of AbbVie from $231.00 to $284.00 and gave the stock an “overweight” rating in a research note on Friday, October 10th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat.com, AbbVie presently has an average rating of “Moderate Buy” and a consensus price target of $234.80.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.